1.	Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Active Age: Under 30 Sponsor: NCI Protocol IDs: COG-AAML0531, AAML0531, NCT00372593
2.	Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Phase: Phase III Type: Treatment Status: Active Age: Under 4 at diagnosis Sponsor: NCI Protocol IDs: COG-AAML0431, AAML0431, NCT00369317
3.	Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 15 to 60 Sponsor: Other Protocol IDs: 2006-0977, NCT00542971
4.	Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 0 to 55 Sponsor: Other Protocol IDs: 8717, NCT00673114
5.	Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer Phase: Phase II Type: Treatment Status: Active Age: 65 and under Sponsor: NCI Protocol IDs: CPMC-IRB-AAAA5571, CPMC-CAMP-016, NCI-G00-1891, NCT00008216
6.	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer Phase: Phase II Type: Supportive care, Treatment Status: Active Age: Under 75 Sponsor: NCI Protocol IDs: FHCRC-1898.00, 5788, NCT00089011
7.	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Phase: Phase II Type: Supportive care, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: FHCRC-1938.00, 5887, NCT00105001
8.	Haploidentical Stem Cell Transplant for Children Less Than Two Years With Hematologic Malignancies Phase: Phase II Type: Treatment Status: Active Age: Under 24 months Sponsor: Other Protocol IDs: INF-T2, NCT00145626
9.	All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab and Theophylline Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2006-0706, NCT00413166
10.	Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) Phase: Phase II Type: Treatment Status: Active Age: 15 to 75 Sponsor: Other Protocol IDs: 2006-0813, NCT00422591
11.	Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: NCI Protocol IDs: CINJ-3330, NCT00161187
12.	Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Phase: Phase II Type: Supportive care, Treatment Status: Active Age: Under 65 Sponsor: Other Protocol IDs: 08-008, NCT00629798
13.	Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Phase: Phase II Type: Treatment Status: Active Age: 15 to 65 Sponsor: Other Protocol IDs: 2007-0835, NCT00656617
14.	T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 11300A, NCT00683046
15.	Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant That Uses Low Dose Chemotherapy in People With Leukemia or Lymphoma (BMT CTN #0604) Phase: Phase II Type: Treatment Status: Active Age: 1 to 70 Sponsor: NCI, NHLBI Protocol IDs: 606, U01 HL069294, NCT00864227
16.	Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies Phase: Phase II Type: Treatment Status: Active Age: 3 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P2 L-D AB, NCT00917826
17.	A Phase 1 Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT Phase: Phase I Type: Treatment Status: Active Age: 1 to 16 Sponsor: Other Protocol IDs: 20010133, NCT00460421
18.	Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant Phase: Phase I Type: Treatment Status: Active Age: 15 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLI-107-08, MSKCC IRB #07-127, NCT00684008
19.	Doxil, Bevacizumab and Temsirolimus Trial Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 and over Sponsor: Other Protocol IDs: 2008-0384, NCT00761644
20.	Sirolimus and Cetuximab in Advanced Malignancies Phase: Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2009-0226, NCT00940381
21.	NK Cell Transplantation for AML Phase: No phase specified Type: Treatment Status: Active Age: 1 to 21 Sponsor: Other Protocol IDs: NKAML, NCT00187096